Peptide Receptor Radionuclide Therapy (PRRT) in 35 Patients with Metastatic Neuroendocrine Neoplasms (NENs): Overall Response and Toxicity Abstract #2060

Introduction: Metastatic or inoperable NeuroEndocrine Neoplasms (NENs) are unresponsive to chemotherapy and targeted therapies. An emerging option is PRRT.
Aim(s): The purpose of this study is to assess the clinical, radiological and biochemical response, as well as the safety of PRRT.
Materials and methods: Thirty five (35) patients with histologically confirmed metastatic or unresectable NET were retrospectively studied. Overall response (OR) was recorded at 6 months and 2 years post treatment, incorporating both partial response (PR) and stable disease (SD). Toxicity was assessed by Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Theodora Liotsou
Keywords: NENs, PRRT

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2242 Diagnostic Utility of Ki-67 as a Mean to Predict the Uptake of Functional Imaging Modalities in Patients with Neuroendocrine Neoplasms
Introduction: Functional imaging with FDG-PET and somatostatin receptors scintigraphy (SRS), play a key role in the diagnosis, treatment and follow-up of patients with neuroendocrine neoplasms (NENs). The proliferative index, ki67, is a reliable pathological marker for grading.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Krystallenia Alexandraki
Keywords: SRS, PET-FDG, ki-67, NENs
#1894 Survival Analysis after i.a. 90Y-DOTATATE PRRT, in Patients with Non-Resectable, Advanced, Progressive, Liver-Dominant Neuroendocrine Neoplasms
Introduction: A
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: MD, PhD Miroslaw L Nowicki
#2290 PRRT in Hindgut and Cancer of Unknown Primary NEN
Introduction: There are limited data regarding PRRT in hindgut and CUP (cancer of unknown primary).
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD, PhD Agnieszka Kolasińska-Ćwikła
Keywords: NENs, PRRT, Hindgut, CUP
#2191 Endocrine Paraneoplastic Syndromes in Patients with Neuroendocrine Neoplasms
Introduction: Endocrine paraneoplastic syndromes (ePNS) result from production of bioactive substances from tumours not related to their expected tissue of origin. Neuroendocrine neoplasms (NENs) have been associated with ectopic secretion of several hormones, but the prevalence of ePNS has only been described in a small number of studies.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Eleftherios Chatzellis
#3057 Epidemiological Features of Patients with NeuroEndocrine Neoplasms (NENs): Preliminary Results of an Observational Study by the Hellenic Society of Medical Oncology (HeSMO)
Introduction: NENs are rare tumors and can grow in almost all tissues. Regardless histological, molecular and imaging characteristics that are indicative of the primary origin, a significant percentage remain of unknown primary.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, MSc, PhD Nikolaos Tsoukalas